Chloroquine Through the Reproductive Lifecycle: Balancing Autoimmune Disease Control and Pregnancy Safety

Few clinical conversations in rheumatology are as nuanced — or as consequential — as the one a physician must have with a woman of childbearing age who depends on chloroquine to manage her autoimmune disease and is now considering pregnancy. The stakes on both sides of the equation are substantial. Uncontrolled lupus or inflammatory arthritis during pregnancy carries documented risks of maternal and fetal complications. Yet the question of whether a medication crosses the placenta, accumulates in fetal tissue, or carries teratogenic potential is one that no clinician or patient can afford to leave unexamined.

This is the core of what some researchers and clinicians have begun calling the "chloroquine-pregnancy paradox": the drug that helps keep a mother's immune system in check may itself introduce a set of questions that require careful, individualized evaluation.

The Pharmacological Foundation: What We Know About Chloroquine and the Placenta

Chloroquine does cross the placenta. This is a pharmacological fact that has been confirmed through multiple studies and is not in dispute. The more clinically relevant questions concern what that placental transfer means for fetal development, whether exposure at therapeutic maternal doses produces measurable harm, and how those findings should inform prescribing decisions.

Animal studies conducted at high doses have documented embryotoxicity and evidence of cochlear and vestibular damage in offspring. However, extrapolating from high-dose animal models to therapeutic human dosing requires significant caution. Human observational data — which constitute the primary evidence base here, given the obvious ethical constraints on randomized trials in pregnant populations — have generally been more reassuring.

A substantial body of retrospective and prospective cohort data, particularly for hydroxychloroquine (chloroquine's closely related analogue), has not demonstrated a consistent signal for major congenital malformations among infants born to mothers taking these medications at standard therapeutic doses. The picture for chloroquine specifically, while somewhat less robust in terms of data volume, follows a broadly similar pattern.

What U.S. Guidelines Currently Recommend

In the United States, major professional bodies have taken a position that can best be described as cautiously permissive, particularly in the context of systemic lupus erythematosus (SLE). The American College of Rheumatology (ACR) and the American College of Obstetricians and Gynecologists (ACOG) both recognize that disease control during pregnancy is a primary clinical objective and that abrupt discontinuation of effective therapy introduces its own set of risks.

For patients with SLE — a disease that disproportionately affects women of reproductive age — the prevailing U.S. clinical consensus supports continuing antimalarial therapy through pregnancy when the medication has been providing effective disease control. This recommendation is grounded in evidence that active lupus flares during pregnancy are associated with preeclampsia, preterm birth, intrauterine growth restriction, and neonatal lupus, outcomes that represent serious and preventable harm.

However, it is important to note that U.S. guidelines are more extensively developed and evidence-supported for hydroxychloroquine than for chloroquine specifically. Clinicians managing patients on chloroquine must often extrapolate from the broader antimalarial evidence base while accounting for chloroquine's somewhat different pharmacokinetic profile and higher potency per milligram.

Where International Guidelines Diverge

The global picture is more varied. European guidelines from bodies such as the European League Against Rheumatism (EULAR) similarly support continuing antimalarial therapy during pregnancy for patients with established autoimmune indications, but the specific language, risk stratification criteria, and recommended monitoring protocols differ across jurisdictions.

In some countries, chloroquine remains more commonly prescribed than hydroxychloroquine due to cost and availability considerations — a reality that shapes clinical practice in ways that U.S.-based physicians may not encounter directly but that affects the global evidence base from which all practitioners draw. Understanding these variations is important for American clinicians treating patients who may have received different guidance abroad or who are consulting international literature.

The Preconception Window: Planning Ahead

For women who are not yet pregnant but are considering conception, the preconception period represents the most valuable window for thoughtful, unhurried clinical planning. This is the time when rheumatologists, obstetricians or maternal-fetal medicine specialists, and the patient herself can collaboratively assess disease activity, review the medication regimen, and establish a monitoring plan for the pregnancy ahead.

Key questions addressed during preconception counseling typically include:

• Is the patient's autoimmune disease currently well-controlled? Entering pregnancy during a period of active disease substantially increases risk. Physicians generally recommend achieving stable disease control for a defined period — often six months or longer — before attempting conception.
• Is the current chloroquine dose the lowest effective dose? Minimizing exposure during pregnancy is a general pharmacological principle, though it must be balanced against the risk of undertreating active disease.
• Are there comorbid conditions or concurrent medications that require adjustment? Many women with lupus or rheumatoid arthritis take multiple medications, some of which — methotrexate and mycophenolate mofetil being prominent examples — carry well-established teratogenic risk and must be discontinued well in advance of conception.
• What is the patient's own risk tolerance and reproductive timeline? Shared decision-making requires understanding the patient's values and circumstances, not just her laboratory values.

Managing the Active Pregnancy

For patients who become pregnant while taking chloroquine, the clinical approach shifts toward heightened monitoring of both maternal disease activity and fetal development. Rheumatologists and maternal-fetal medicine specialists typically co-manage these pregnancies, with visit frequency and ultrasound surveillance calibrated to disease severity and individual risk factors.

One specific concern that merits mention is the potential for neonatal lupus in infants born to mothers with anti-Ro/SSA or anti-La/SSB antibodies — a complication related to maternal antibody transfer rather than to chloroquine use itself, but one that requires monitoring regardless of the medication regimen. Some research suggests that antimalarial use may actually reduce the risk of certain neonatal lupus manifestations, though this data remains preliminary.

Flare management during pregnancy requires particular skill, as the range of available therapeutic options narrows considerably. Chloroquine's relative safety profile compared to many immunosuppressive alternatives makes it, paradoxically, a more attractive option during pregnancy for patients who require ongoing disease control.

The Postpartum Period and Breastfeeding

The postpartum period introduces its own set of considerations. Autoimmune disease activity frequently increases in the weeks following delivery, a well-documented phenomenon that makes medication management during this period especially important. For women who wish to breastfeed, the question of chloroquine transfer into breast milk arises.

Chloroquine is detectable in human breast milk, though the amounts transferred to infants are generally considered low. Current guidance from most U.S. and international bodies does not categorically contraindicate breastfeeding for women taking chloroquine at therapeutic doses, but individualized discussions with a pediatrician and the prescribing physician are recommended.

Toward a More Individualized Framework

Perhaps the most important takeaway from the current evidence base is that no single, universal answer governs chloroquine use across the entire reproductive lifecycle. A woman with well-controlled lupus planning her first pregnancy faces a different clinical calculus than one experiencing a disease flare at 20 weeks of gestation, or one who is postpartum and struggling with a recurrence of inflammatory symptoms while nursing a newborn.

What the evidence does support clearly is that the risks of uncontrolled autoimmune disease during pregnancy are real, documented, and clinically serious — and that chloroquine, used at appropriate doses with appropriate monitoring, represents a reasonable therapeutic tool in carefully selected patients. The goal for clinicians and patients alike is not to eliminate all medication exposure during pregnancy, which is neither achievable nor desirable for many women with chronic conditions, but to make informed, evidence-guided decisions that respect both the complexity of the science and the individuality of the patient.